RS17 peptide

RS17 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-RRYKQDGGWSHWSPWSS-NH2

H-Arg-Arg-Tyr-Lys-Gln-Asp-Gly-Gly-Trp-Ser-His-Trp-Ser-Pro-Trp-Ser-Ser-NH2

17

95.42%

C₉₆H₁₃₁N₃₁O₂₅

2119.25

Synthetic

Powder

RS17 is a peptide which binds to the transmembrane protein CD47 and blocks the interaction of CD47 with the regulatory membrane glycoprotein signal regulatory protein α (SIRPα). In normal cells, CD47 interaction with SIRPα on the macrophage surface membrane sends a phagocytosis inhibiting signal, a mechanism which can be taken advantage of by cancer cells to enable immune escape. RS17 blockade of the CD47 and SIRPα interaction in cancer cells can prevent phagocytosis evasion, and treatment with RS17 significantly promotes the removal of tumour cells by macrophages. RS17 has a strongly inhibitory effect on tumour growth in a cancer xenograft mouse model.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Wang et al (2021) An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity. Cancer Med. 10(6) 2125 PMID: 33629544

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.